Pardes Biosciences Management
Management criteria checks 1/4
Pardes Biosciences' CEO is Tom Wiggans, appointed in Mar 2022, he has a tenure of 1.25 years. His total yearly compensation is $5.26M , comprised of 9.9% salary and 90.1% bonuses, including company stock and options. He directly owns 0.083% of the company’s shares, worth $92.50K. The average tenure of the management team and the board of directors is 2.3 years and 2.2 years respectively.
Key information
Tom Wiggans
Chief executive officer
US$5.3m
Total compensation
| CEO salary percentage | 9.9% |
| CEO tenure | 1.3yrs |
| CEO ownership | 0.08% |
| Management average tenure | 2.3yrs |
| Board average tenure | 2.2yrs |
Recent management updates
Recent updates
Here's Why We're Watching Pardes Biosciences' (NASDAQ:PRDS) Cash Burn Situation
Jan 20
We Think Pardes Biosciences (NASDAQ:PRDS) Needs To Drive Business Growth Carefully
Oct 01Pardes begins phase 2 trial of oral drug PBI-0451 for COVID-19
Sep 13Pardes Biosciences GAAP EPS of -$0.48
Aug 15Pardes Biosciences (NASDAQ:PRDS) Is In A Good Position To Deliver On Growth Plans
Jun 14Pardes Biosciences: Advancing A Viral Protease Inhibitor Platform
Jan 21CEO Compensation Analysis
| Date | Total Comp. | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2023 | n/a | n/a | -US$93m |
| Dec 31 2022 | US$5m | US$521k | -US$97m |
Compensation vs Market: Tom's total compensation ($USD5.26M) is above average for companies of similar size in the US market ($USD749.64K).
Compensation vs Earnings: Insufficient data to compare Tom's compensation with company performance.
CEO
Tom Wiggans (71 yo)
1.3yrs
Tenure
US$5,255,958
Compensation
Mr. Thomas G. Wiggans, also known as Tom, serves as Independent Director at CymaBay Therapeutics, Inc. since April 2021. He serves as an Executive Chairman of Follica, Inc. since January 2021. He serves as...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman of the Board | 1.3yrs | US$5.26m | 0.083% $ 92.5k | |
| Founder & Director | no data | US$3.52m | 9.47% $ 10.5m | |
| Chief Financial Officer | 2.4yrs | US$1.82m | 0.53% $ 586.0k | |
| General Counsel & Corporate Secretary | 2.4yrs | no data | 0.35% $ 390.7k | |
| Chief Business Officer | 2.1yrs | no data | 0.035% $ 38.9k |
2.3yrs
Average Tenure
56yo
Average Age
Experienced Management: PRDS's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman of the Board | 1.3yrs | US$5.26m | 0.083% $ 92.5k | |
| Founder & Director | 3.3yrs | US$3.52m | 9.47% $ 10.5m | |
| Director | 2.4yrs | US$110.69k | no data | |
| Independent Director | 2.4yrs | US$170.69k | 0.12% $ 130.2k | |
| Independent Director & Member of Scientific Advisory Board | 2.8yrs | US$153.69k | 0.12% $ 130.2k | |
| Independent Director | 2.4yrs | US$163.19k | 2.27% $ 2.5m | |
| Independent Director | less than a year | US$147.00k | 0% $ 0 | |
| Independent Director | 1.9yrs | US$161.19k | 0% $ 0 | |
| Lead Independent Director | less than a year | US$146.94k | 0% $ 0 | |
| Independent Director | 1.9yrs | US$153.69k | 0% $ 0 | |
| Member of Commercial Advisory Board | no data | no data | no data |
2.2yrs
Average Tenure
62.5yo
Average Age
Experienced Board: PRDS's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.